0 Items
Select Page

Crimean Congo Hemorrhagic Fever

Crimean-Congo haemorrhagic fever (CCHF) virus causes a viral haemorrhagic fever transmitted by ticks. CCHF virus responsible for severe outbreaks in humans with a high case fatality ratio of 10-40%. CCHF is endemic in all of Africa, the Balkans, the Middle East and in Asia.

Using our mammalian expression system, we have developed CCHF glycoprotein and nucleoprotein antigens, both of which may be used to detect serological responses to infection.

Crimean Congo Hemorrhagic Fever Background

Crimean Congo Haemorrhagic Fever (CCHF) is a tick-borne infection that is geographically widespread across Africa, Asian, the Middle East and Eastern Europe. It is caused by Crimean Congo haemorrhagic fever virus (CCHFV) – an enveloped, single-stranded RNA virus that belongs to the genus Nairovirus and Bunyaviridae family.

The CCHF virus is primarily maintained in domestic animals and livestock by ticks of the Hyalomma genus (1). However, the virus can be transmitted to humans by CCHFV-infected ticks or through contact with CCHFV-infected animal tissue. Human-to-human transmission can also occur which poses a significant risk to healthcare workers.

In humans, the incubation period of the virus varies with route of exposure. Whilst infected animals remain asymptomatic, CCHFV infection in humans results in a range of clinical symptoms including fever, myalgia, nausea, and headaches before the disease progresses to the haemorrhagic stage (2). According to the World Health Organization (WHO), CCHF can be fatal in 10-40% of cases (3).

Since CCHF was first described in Crimea, in 1944, sporadic outbreaks have occurred globally. In 2015, CCHFV was characterised by the WHO as an emerging virus, likely to cause a severe epidemic and which may present a public health emergency (4). Currently, CCHF viral infection is diagnosed by isolating the virus in early stages of the infection and then by serology, immunofluorescence and molecular techniques. While prophylactic vaccines are in development a safe and effective vaccine has not yet been licensed for use in humans.

References

  1. Spengler, J.R. et al (2016) Seroepidemiological Studies of Crimean-Congo Hemorrhagic Fever Virus in Domestic and Wild Animals. PLoS Negl Trop Dis. 7:10(1):e0004210.
  2. Shayan, S. et al (2015) Crimean-Congo Hemorrhagic Fever. Lab Med. 46:180-9.
  3. World Health Organization – Media centre: Crimean-Congo haemorrhagic fever.
  4. WHO list of top emerging diseases

Crimean Congo Hemorrhagic Fever Antigens

We offer two antigens for CCHFV: glycoprotein N and nucleoprotein, for studies on CCHF biology and serological responses to infection. Both are prepared in our proprietary mammalian cell expression system to ensure correct glycosylation and native folding.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

14 + 11 =

Live Customer Feedback

Join our mailing list

* indicates required